Drug development

The pipeline of drugs in development in French biotechs saw a significant increase in 2008, but the funding climate may undermine this advance, says France Biotech.

Everyone’s strapped for cash – except pharma. But the latest spending spree is no more of a fix for expiring patents than botox is for ageing skin, writes Nuala Moran.